Document is current
Any future updates will be listed below
-
Authors
Halip, Liliana https://orcid.org/0000-0002-2600-0186
Avram, Sorin https://orcid.org/0000-0002-4816-7446
Overington, John P. https://orcid.org/0000-0002-5859-1064
Al-Lazikani, Bissan https://orcid.org/0000-0003-3367-2519
Curpan, Ramona https://orcid.org/0000-0003-0268-7291
Sirimulla, Suman
Pushechnikov, Alexei https://orcid.org/0000-0003-4404-1851
Beccari, Andrea Rosario https://orcid.org/0000-0001-6830-2695
Savchuck, Nikolay
Oprea, Tudor I. https://orcid.org/0000-0002-6195-6976
- License Information
-
More Information
Article History
Accepted: 7 August 2026
First Online: 21 September 2026
Ethics
Competing interests: J.P.O. is an employee of Xyme AI. S.S. is an employee of Expert Systems. A.P. and N.S. hold financial interests in Torrey Pines Investments. A.R.B. and T.I.O. are employees of Dompé farmaceutici. B.A.-L. holds financial interests in Xyme, AstraZeneca and Recursion Pharmaceuticals following its acquisition of Exscientia; has served on scientific advisory boards for and/or received consulting fees from Astex Pharmaceuticals, AstraZeneca, GSK, Novo Nordisk, Santé Ventures and Astellas Pharma; and also holds or has held board, leadership or scientific advisory roles with Blood Cancer United, Cancer Research UK, the Chemical Probes Portal, the New York Genome Consortium and Open Targets. T.I.O. was an employee of Roivant Sciences and Expert Systems, and had financial interests in Roivant Sciences, Expert Systems and InSilico Medicine when this Review was written. The other authors declare no competing interests.
